EDEN.L

Eden Research Plc
Eden Research plc - Bioinsecticide Field Trials
27th June 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0426U
Eden Research plc
27 June 2024
 

27 June 2024

A picture containing text, clipart Description automatically generated 


Eden Research Plc

("Eden" or "Company")

 

Bioinsecticide Field Trials


Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technologies for use in the global crop protection, animal health and consumer products industries, is pleased to provide an update on the development of its bioinsecticide product following the receipt of recent field trial reports. The trials, which were undertaken by several potential commercial partners for the product, as well as by Eden, represent a significant milestone in the process of bringing the Company's new bioinsecticide to market as Eden continues to develop and expand its product portfolio, in line with its business strategy.

In the more than 30 laboratory trials and more than 140 field trials run in Europe and the United States, the developmental bioinsecticide product was tested against aphids, spider mites, whiteflies and other target pests at various stages of their development. Results showed strong efficacy against all life stages of these key pests and equivalent or superior performance when compared with registered biological reference products produced by some of the world's leading biochemical companies.

Every year, up to 40% of crops are lost due to plant pests and diseases, whilst the United Nations estimates that 50% more food will be needed to feed the world's growing population by 2050. Insects remain one of the most significant challenges to farming efforts across the globe, causing both direct and indirect damage to crops through feeding and the transmission of disease, costing the global economy an estimated $70 billion a year, according to the UN's Food and Agriculture Organization. At the same time, conventional insecticide products face increased regulatory scrutiny due to their potential for harmful effects on the environment and wildlife, including bees and other beneficial insects. Demand is high for sustainable products, like Eden's bioinsecticide, that can provide farmers with sustainable and competitive alternatives, providing similar ease-of-use, efficacy, safety, cost and reliability, representing a significant global market opportunity for Eden.

Sean Smith, Chief Executive Officer of Eden Research, commented:

 

"These promising results further demonstrate Eden's ability to develop market-leading biological formulations at a time when conventional insecticide products are being phased out due to regulatory action. The trials, undertaken by Eden and independently by several potential commercial partners interested in gaining rights to the product, show extremely promising efficacy and consistency in combating these pests known to critically impact crop yields. This is an exciting step in our journey to bring this product to farmers who are looking for effective, sustainable solutions to control pests, whilst also making further progress against our product diversification and business growth objectives."

 

For further information contact:

 

Eden Research plc


Sean Smith
Alex Abrey

 

www.edenresearch.com

01285 359 555



Cavendish Capital Markets Limited (Nominated advisor and broker)

 

Giles Balleny / George Lawson (corporate finance)
Charlie Combe (corporate broking)
Michael Johnson (sales)

 

020 7220 0500



Hawthorn Advisors (Financial PR)

 

Victoria Ainsworth

eden@hawthornadvisors.com

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's seed treatment product, Ecovelex was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, U.S. and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RESFLFERRAIRFIS]]>
TwitterFacebookLinkedIn